03/24/23 7:00 AMNasdaq : PPBT Purple Biotech Reports Temporary Medical Leave of CEO Gil EfronPurple Biotech Ltd. ("Purple Biotech", or the "Company") (NASDAQ/TASE: PPBT), aRHEA-AIneutral
03/16/23 7:00 AMNasdaq : PPBT clinical trialPurple Biotech Reports Biomarker Data from CM24 Phase 1 Dose Escalation StudyPurple Biotech Ltd. ("Purple Biotech", or the "Company") (NASDAQ/TASE: PPBT), a clinical-stage companyRHEA-AIneutral
02/14/23 7:01 AMNasdaq : PPBT clinical trialPurple Biotech Announces First Patient Dosed in Open Label, Randomized Part of CM24 Phase 2 Clinical TrialPurple Biotech Ltd. (“Purple Biotech” or “the Company”) (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class, effective and durable therapies that harness the power of the tumor microenvironment to overcome tumor immune evasionRHEA-AIneutral
02/08/23 7:12 AMNasdaq : PPBT earningsPurple Biotech Reports Fourth Quarter and Full-Year 2022 Financial ResultsPurple Biotech Ltd. (“Purple Biotech” or “the Company”) (NASDAQ/TASE: PPBT), a clinical-stage company developingRHEA-AIneutral
02/02/23 7:00 AMNasdaq : PPBT acquisitionPurple Biotech Expands Pipeline of First-in-Class Therapeutics with Acquisition of Immunorizon and Its Portfolio of Tri-Specific Antibodies for the Treatment of Cancer Purple Biotech Ltd. (NASDAQ/TASE:RHEA-AIneutral
01/03/23 7:00 AMNasdaq : PPBT Purple Biotech and Mor Research Applications Announce Research Collaboration to Identify Promising Investigational Oncology TreatmentsAs a subsidiary of Clalit Healthcare Services, Israel’s largest HMO, Mor Research Applications brings Purple Biotech first access to research conducted at 14 hospitals The collaboration with Mor Research Applications has the potential to accelerate Purple Biotech’s future pipeline expansion inRHEA-AIvery positive
11/15/22 7:00 AMNasdaq : PPBT Purple Biotech Presents New Data on Mechanism of Action for CM24 at the AACR Special Conference: Cancer MetastasisPurple Biotech Ltd. ("Purple Biotech", or the "Company") (NASDAQ/TASE: PPBT), aRHEA-AIneutral
11/10/22 7:00 AMNasdaq : PPBT conferencesPurple Biotech to Present at the Jefferies London Healthcare ConferencePurple Biotech Ltd. ("Purple Biotech", or the "Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class, effective and durable therapies by harnessing the power of the tumor microenvironment to overcomeRHEA-AIneutral
11/08/22 7:53 AMNasdaq : PPBT earningsPurple Biotech Reports Third Quarter 2022 Financial ResultsPurple Biotech Ltd. ("Purple Biotech", or the "Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class, effective andRHEA-AIneutral
11/02/22 7:37 AMNasdaq : PPBT managementPurple Biotech Appoints Lior Fhima as Chief Financial OfficerPurple Biotech Ltd. ("Purple Biotech", or the "Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class, effective and durable therapies by harnessing the power ofRHEA-AIvery positive